{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:36:06Z","timestamp":1793806566344,"version":"4.6.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Acute heart failure (AHF) is a serious medical condition with considerable morbidity and mortality ranging from 20%\u201330% within the first month following hospital admission. We aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors administered within the first five days of hospitalization for AHF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We utilized various electronic resources such as MEDLINE, Embase, and the Cochrane Library to retrieve relevant randomized controlled trials (RCTs). The meta-analysis was performed using Revman, where the risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used for dichotomous and continuous variablesrespectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of seven trials were included in this review. SGLT2 inhibitors were associated with decreased all-cause mortality (RR\u2009=\u20090.61, 95% CI\u2009=\u20090.40, 0.95; <jats:italic>P<\/jats:italic>\u2009=\u20090.03), worsening of HF (RR\u2009=\u20090.59, 95%CI\u2009=\u20090.36, 0.97;<jats:italic>P<\/jats:italic>\u2009=\u20090.04), and GFR (MD: 1.05, 95% CI\u2009=\u20090.68, 1.43; <jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.00001) compared with the control group. There were no significant differences between the two groups regarding readmission for HF, cardiovascular mortality, AKI, hypoglycemia, hypotension, and diuretic efficiency. SGLT2 inhibitors were associated with improved KCCQ-CSS scores (MD: \u22123.82, 95% CI\u2009=\u2009\u22127.51, \u22120.13; <jats:italic>P<\/jats:italic>\u2009=\u20090.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2 inhibitors demonstrate overall clinical benefits and a favorable safety profile in acute heart failure, although their impact on readmission rates is limited. Further research is needed to refine patient selection and optimize treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024571563<\/jats:uri>, PROSPERO (CRD42024571563).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1543153","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:38:56Z","timestamp":1746077936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Ali Ibrahim","family":"Rahil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirth","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romman","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajitha","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanif Al","family":"Majidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Gajjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wodwentzky","family":"Lefranc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Deeksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"Lingegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeh","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000509353","article-title":"Acute cardiorenal syndrome: models and heart-kidney connectors","volume":"144","author":"Funahashi","year":"2020","journal-title":"Nephron"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-021-01266-x","article-title":"Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients","volume":"20","author":"Xiang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/ehf2.13955","article-title":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure","volume":"9","author":"Thiele","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.47391\/JPMA.9813","article-title":"Early initiation of dapagliflozin and its effect on health related quality of life in acute heart failure: a randomised controlled trial","volume":"74","author":"Fatima Gilani","year":"2024","journal-title":"JPMA J Pak Med Assoc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e001936","DOI":"10.1136\/openhrt-2021-001936","article-title":"Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study","volume":"9","author":"Charaya","year":"2022","journal-title":"Open Heart"},{"key":"B26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality: insights from the EMPA-REG OUTCOME trial","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1\u2014receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2019.18598","article-title":"Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial","volume":"322","author":"Kozhuharov","year":"2019","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"B38","article-title":"A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure-Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68).","year":"2025"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-Glucose cotransporter-2 inhibitors in heart failure: a meta-analysis of randomized clinical trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e42113","DOI":"10.7759\/cureus.42113","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in heart failure: an umbrella review","volume":"15","author":"Roy","year":"2023","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/ehjqcco\/qcab072","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials","volume":"8","author":"Ahmad","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.31083\/j.rcm2311374","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure with a preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"23","author":"Lou","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"12642","DOI":"10.1161\/circ.144.suppl_1.12642","article-title":"Heart failure prognosis in diabetic patients on SGLT2 (sodium-glucose cotransporter-2) inhibitors: a systematic review and meta-analysis","volume":"144","author":"Nso","year":"2021","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.3390\/ijms25063122","article-title":"The role of sodium-glucose co-transporter-2 inhibitors on diuretic resistance in heart failure","volume":"25","author":"Stachteas","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"key":"B48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ejhf.35","article-title":"The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?","volume":"16","author":"Verbrugge","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2288-14-79","article-title":"Systematic review of methods for individual patient data meta- analysis with binary outcomes","volume":"14","author":"Thomas","year":"2014","journal-title":"BMC Med Res Methodol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1543153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:38:57Z","timestamp":1746077937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1543153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2025.1543153"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1543153","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1543153"}}